This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Revisiting NTRKs as an emerging oncogene in hematological malignancies
Leukemia Open Access 24 September 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Eguchi M, Eguchi-Ishimae M, Tojo A, Morishita K, Suzuki K, Sato Y et al. Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25). Blood 1999; 93: 1355–1363.
Tognon C, Garnett M, Kenward E, Kay R, Morrison K, Sorensen PH . The chimeric protein tyrosine kinase ETV6-NTRK3 requires both Ras-Erk1/2 and PI3-kinase-Akt signaling for fibroblast transformation. Cancer Res 2001; 61: 8909–8916.
Okabe M, Kunieda Y, Shoji M, Nakane S, Kurosawa M, Tanaka J et al. Megakaryocytic differentiation of a leukemic cell line, MC3, by phorbol ester: induction of glycoprotein IIb/IIIa and effects on expression of IL-6, IL-6 receptor, mpl and GATA genes. Leuk Res 1995; 19: 933–943.
Rush J, Moritz A, Lee KA, Guo A, Goss VL, Spek EJ et al. Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat Biotechnol 2005; 23: 94–101.
Walters DK, Mercher T, Gu TL, O’Hare T, Tyner JW, Loriaux M et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell 2006; 10: 65–75.
Lamballe F, Tapley P, Barbacid M . TrkC encodes multiple neurotrophin-3 receptors with distinct biological properties and substrate specificities. EMBO J 1993; 12: 3083–3094.
Tsoulfas P, Stephens RM, Kaplan DR, Parada LF . TrkC isoforms with inserts in the kinase domain show impaired signaling responses. J Biol Chem 1996; 271: 5691–5697.
Liu Q, Schwaller J, Kutok J, Cain D, Aster JC, Williams IR et al. Signal transduction and transforming properties of the TEL-TRKC fusions associated with t(12;15)(p13;q25) in congenital fibrosarcoma and acute myelogenous leukemia. EMBO J 2000; 19: 1827–1838.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)
Supplementary information
Rights and permissions
About this article
Cite this article
Gu, TL., Popova, L., Reeves, C. et al. Phosphoproteomic analysis identifies the M0-91 cell line as a cellular model for the study of TEL-TRKC fusion-associated leukemia. Leukemia 21, 563–566 (2007). https://doi.org/10.1038/sj.leu.2404555
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404555
This article is cited by
-
Revisiting NTRKs as an emerging oncogene in hematological malignancies
Leukemia (2019)
-
A new ETV6-NTRK3 cell line model reveals MALAT1 as a novel therapeutic target - a short report
Cellular Oncology (2018)